Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp in CMML and MF
NCT02268253Phase 2Completed
- Sponsor
- Stemline Therapeutics
- Start
- Feb 2016
- Primary completion
- Mar 2023
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, open-label trial of tagraxofusp in chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF) (6 arms), sponsored by Stemline Therapeutics. Primary endpoints: Dose-limiting Toxicities at 21 days and Objective Response Rate at 1145 days. Started Feb 2016; status: completed.
02
Drugs
tagraxofusp
03
Conditions
chronic myelomonocytic leukemia (CMML)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02268253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268253.